Formulation Literacy / Product-standard route
Full-Spectrum Formulation Standard
Use this standard when a reader wants to compare CBD, CBG, CBN, THC, full-spectrum, broad-spectrum, and isolate preparations. The answer should be composition first, evidence second, and product choice only after safety and context are understood.
Principles
What this standard should mean in public.
Composition first
A formulation page should disclose cannabinoid profile, route, serving size, carrier, flavoring, and relevant excipients.
Evidence stays formulation-specific
A study on an isolate, drug product, inhaled product, or high-dose oral preparation should not silently support a different formulation.
Minor cannabinoids need humility
CBG, CBN, CBC, THCV, and rare cannabinoids are exciting, but many public claims still outrun human evidence.
Proof Routes
Where readers can inspect the vocabulary and risk context.
Full-spectrum
The dictionary route for what full-spectrum usually means and why details matter.
Isolate
The route for separating isolated-compound evidence from whole-extract language.
Route of administration
The route for understanding why oral, topical, inhaled, and other delivery paths cannot be swapped casually.
Build Standard
What needs to exist before product pages scale.
- Make labels data-rich Publish cannabinoid profile, serving size, route, carrier, and excipient details in a structured format.
- Route every claim Connect formulation language to compound, safety, and dictionary pages rather than unsupported benefit copy.
- Build comparison pages Let readers compare CBD, CBG, CBN, THC, full-spectrum, broad-spectrum, and isolate without being pushed into a medical conclusion.
Do Not Say
Guardrails that keep trust language honest.
- Do not use entourage-effect language as a blanket proof of benefit.
- Do not treat isolated-compound findings as proof for every full-spectrum product.
- Do not ignore THC, impairment, drug-interaction, or product-quality context when discussing full-spectrum products.